1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

Lead Therapy Into Clinic This Year

 
• By Lisa Takagi

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

RegCell HQ
A Japanese cell therapy venture RegCell relocated its HQ from Japan to US with $48.5m financing. (Shutterstock)

Japanese regulatory T-cell (T-reg) venture RegCell has raised new funding to progress its autoimmune-focused pipeline, while relocating its headquarters to the US to better access expertise, capital and partnerships.

The academic research spinout said it had closed an oversubscribed seed round, raising $8.5m from Japanese venture capital funds co-led by The University of Tokyo Edge Capital Partners (UTEC) and Fast Track Initiatives

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.